1-4 of 4
Zuomei Li
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

Clinical Trials & Observations
Guillermo Garcia-Manero, Sarit Assouline, Jorge Cortes, Zeev Estrov, Hagop Kantarjian, Hui Yang, Willie M. Newsome, Wilson H. Miller, Jr, Caroline Rousseau, Ann Kalita, Claire Bonfils, Marja Dubay, Tracy-Ann Patterson, Zuomei Li, Jeffrey M. Besterman, Gregory Reid, Eric Laille, Robert E. Martell, Mark Minden
Journal: Blood
Blood (2008) 112 (4): 981–989.
https://doi.org/10.1182/blood-2007-10-115873
Published: 2008
Includes: Supplemental data
Journal Articles

Treatment of Relapsed or Refractory Lymphoma with the Oral Isotype-Selective Histone Deacetylase Inhibitor MGCD0103: Interim Results from a Phase II Study.

Anas Younes, MD, Amanda Wedgwood, LPN, Peter McLaughlin, MD, Charalambos Andreadis, MD, Sarit E. Assouline, MD, Zuomei Li, Ph.D, Robert E. Martell, MD, Marja Dubay, BSc., Tracy-Ann Patterson, BSc.N, Michelle R. Ward, MD, Michael Crump, MD
Journal: Blood
Blood (2007) 110 (11): 2571.
https://doi.org/10.1182/blood.V110.11.2571.2571
Published: 2007
Journal Articles

Isotype-Selective HDAC Inhibitor MGCD0103 Decreases Serum TARC Concentrations and Produces Clinical Responses in Heavily Pretreated Patients with Relapsed Classical Hodgkin Lymphoma (HL).

Anas Younes, MD, Barbara Pro, MD, Michelle Fanale, MD, Peter McLaughlin, MD, Sattva Neelapu, MD, Luis Fayad, MD, Amanda Wedgwood, RN, APN, Daniela Buglio, MD, Tracy Patterson, RN, Marja Dubay, BSc., Zuomei Li, Ph.D., Robert E. Martell, MD, Ph.D., M. Renee Ward, MD, Ph.D., R. Gregory Bociek, MD, MSc., FRCPC
Journal: Blood
Blood (2007) 110 (11): 2566.
https://doi.org/10.1182/blood.V110.11.2566.2566
Published: 2007
Journal Articles

Phase I/II Study of the Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor MGCD0103 in Combination with Azacitidine in Patients (pts) with High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML).

Guillermo Garcia-Manero, MD, Allen S. Yang, MD, PhD, Francis Giles, MD, Stefan Faderl, Farhad Ravandi, MD, Jorge Cortes, MD, Willie M. Newsome, RN, Jean-Pierre Issa, MD, Tracy-Ann Patterson, Marja Dubay, Zuomei Li, Hagop Kantarjian, MD, Robert E. Martell, MD
Journal: Blood
Blood (2006) 108 (11): 1954.
https://doi.org/10.1182/blood.V108.11.1954.1954
Published: 2006